Innovation Sponsors


Allergan plc (NYSE: AGN), is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative treatments that help people around the world live longer, healthier lives.
Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas: medical aesthetics, eye care, central nervous system and gastroenterology. As part of Allergan's approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

Azura Ophthalmics

Azura Ophthalmics Limited is a clinical-stage biotechnology company headquartered in Tel Aviv, Israel. Azura Ophthalmics is developing an innovative portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for Meibomian Gland Dysfunction (MGD) and other Lid Margin Diseases such as Blepharitis. and Contact Lens Discomfort. By targeting the root cause of MGD, Azura Ophthalmics brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD. Azura Ophthalmics is underpinned by an experienced management team with an established record of successfully developing and launching both novel devices and pharmaceuticals for the treatment of ocular surface diseases.


Eyenovia, Inc. (NASDAQ: EYEN), a pre-NDA stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology to improve the therapeutic index, delivery and comfort of drugs in pediatric myopia, presbyopia and pharmaceutical mydriasis.

Novartis Pharmaceutical Corporation

Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.

Oyster Point Pharma

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

Sight Sciences

In 2011, Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease. Supported by leading medical technology and private equity investors, Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the OMNI™ Surgical System, TRAB®360 and VISCO360® for use by ophthalmologists. Its non-surgical product portfolio consists of its TearCare™ technologies for use by ophthalmologists and optometrists.

SightGlass Vision

SightGlass Vision, Inc. is a clinical-stage medtech startup company focused on ending myopia.


TearClear is developing a platform of products, for multiple indications, where the preservative stays in the bottle, but is preservative free on the eye. We are the only company that can do this approach. This is important since preservatives, in particular BAK, cause ocular surface damage for over 25% of chronic users. TearClear meets the critical unmet need for the patient while providing an unmatched safety profile.

TearClear offers the potential for improved outcomes to patients who rely on glaucoma and dry-eye drugs. With demonstrated safety and efficacy, TearClear is responding to the interests of both patients, who prefer multi-use bottles over single-dose, and physicians, who prefer preservative-free therapies.

Carl Zeiss Meditec

Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.